Selective estrogen receptor modulators

1. A compound of Formula (I):

or pharmaceutically acceptable salt form thereof,

wherein R 1 is

R 2 is selected from the group consisting of H, C 1-8 alkyl and halo;

R 3 is selected from the group consisting of H, C 1-8 alkyl, halo, and CN;

alternatively R 2 and R 3 , together with the atoms to which they are attached, form a six- or seven-membered ring structure where one or more of the atoms forming the ring may be oxygen;

R 4 is selected from the group consisting of H, OH, C 1-8 alkyl, OC 1-8 alkyl and halo;

R 5 is selected from the group consisting of H, OH, CN, nitro, C 1-8 alkyl, OC 1-8 alkyl and halo;

R 8 is selected from the group consisting of aryl, C 1-8 alkyl, OH, and OC 1-8 alkyl, wherein said R 8 is optionally substituted with 1 to 2 substituents selected from halo, nitro, OH, CN, C 1-4 alkyl, OC 1-4 alkyl, NH 2 , and NHC(O)OC(CH 3 ) 3 ; and

the bond represented by a broken line and a solid line is an optional double bond.

2. A compound according to claim 1 wherein R 2 and R 3 together with the atoms to which they are attached form a seven-membered ring.

3. A compound according to claim 1 wherein R 2 and R 3 together with the atoms to which they are attached form a six membered ring.

4. A compound according to claim 1 wherein R 3 is CH 3 .

5. A compound according to claim 1 wherein R 3 is CN.

6. A compound according to claim 1 wherein R 2 is H.

7. A compound according to claim 1 selected from the group consisting of:

v) N-{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acryloyl}-methanesulfonamide;

w) N-{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acryloyl}-benzenesulfonamide;

x) N-{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acryloyl}phenyl-methanesulfonamide;

y) N-{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acryloyl}-3-nitro-benzenesulfonamide;

z) N-{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acryloyl-4-nitro-benzenesulfonamide;

aa) N-{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acryloyl}-2-methyl-benzenesulfonamide;

ab) N-{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acryloyl}-4-methyl-benzenesulonamide;

ac) N-{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acryloyl}-2-nitro-benzenesulfonamide;

ad) N-{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acryloyl}trifluoro-methanesulfonamide;

ae) N-{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acryloyl}-4-methoxy-benzenesulfonamide;

af) 4-Chloro-N-{3-[4-(1,2-diphenyl-but-1-enyl)-phenyl]-acryloyl}-benzenesulfonamide;

ag) 4-Cyano-N-{3-[4-(1,2-diphenyl-but-1-enyl)-phenyl]-acryloyl}-benzenesulfonamide;

ah) N-{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acryloyl}-3-trifluoromethyl-benzenesulfonamide;

ai) 2-Chloro-N-{3-[4-(1,2-diphenyl-but-1-enyl)-phenyl]-acryloyl}-benzenesulfonamide;

aj) 3-Chloro-N-{3-[4-(1,2-diphenyl-but-1-enyl)-phenyl]-acryloyl}-benzenesulfonamide;

ak) N-{3-[4-(2-Phenyl-3,4-dihydro-naphthalen-1-yl)-phenyl]-acryloyl}-methanesulfonamide;

al) N-{3-[4-(2-Phenyl-3,4-dihydro-naphthalen-1-yl)-phenyl]-acryloyl}-benzenesulfonamide;

am) N-{3-[4-(3-Phenyl-2H-chromen-4-yl)-phenyl]-acryloyl}-methanesulfonamide;

an) N-{3-[4-(3-Phenyl-2H-chromen-4-yl)-phenyl]-acryloyl}-benzenesulfonamide;

ap) N-{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acryloyl}-2-trifluoromethyl-benzenesulfonamide;

aq) N-{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acryloyl}-3-methyl-benzenesulfonamide;

ar) N-{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acryloyl}-4-hydroxy-benzenesulfonamide;

as) N-{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acryloyl}-3-methoxy-benzenesulfonamide;

at) N-{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acryloyl}-4-trifluoromethyl-benzenesulfonamide;

au) N-{3-(4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acryloyl}-3-hydroxy-benzenesulfonamide;

aw) N-{3-[4-(6-Phenyl-8,9-dihydro-7H-benzocyclohepten-5-yl)-phenyl]-acryloyl}-methanesulfonamide;

ax) N-{3-[4-(6-Phenyl-8,9-dihydro-7H-benzocyclohepten-5-yl)-phenyl]-acryloyl}-benzenesulfonamide;

ay) Phenyl-N-(3-[4-(2-phenyl-3,4-dihydro-naphthalen-1-yl)-phenyl]-acryloyl}-methanesulfonamide;

az) Phenyl-N-{3-[4-(6-phenyl-8,9-dihydro-7H-benzocyclohepten-5-yl)-phenyl]-acryloyl}-methanesulfonamide;

ba) 3-Chloro-propane-1-sulfonic acid {3-[4-(1,2-diphenyl-but-1-enyl)-phenyl]-acryloyl}-amide;

bb) (4-{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acryloylsulfamoyl)-phenyl)-carbamic acid tert-butyl ester;

bd) 4-Amino-N-{3-[4-(1,2-diphenyl-but-1-enyl)-phenyl]-acryloyl}-benzenesulfonamide;

be) Ethanesulfonic acid {3-[4-(1,2-diphenyl-but-1-enyl)-phenyl]-acryloyl}-amide;

bg) Propane-2-sulfonic acid {3-[4-(1,2-diphenyl-but-1-enyl)-phenyl]-acryloyl}-amide;

bh) N-{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acryloyl}-(4-fluoro-phenyl)-methanesulfonamide;

bi) 4-{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acryloylsulfamoyl}-benzoic acid;

bk) 2,2,2-Trifluoro-ethanesulfonic acid {3-[4-(1,2-diphenyl-but-1-enyl)-phenyl]-acryloyl}-amide;

bl) 3-Chloro-propane-1-sulfonic acid {3-[4-(6-phenyl-8,9-dihydro-7H-benzocyclohepten-5-yl)-phenyl]-acryloyl}-amide;

bm) Trifluoro-N-{3-[4-(6-phenyl-8,9-dihydro-7H-benzocyclohepten-5-yl)-phenyl]-acryloyl}-methanesulfonamide;

bq) (4-Fluoro-phenyl)-N-{3-[4-(6-phenyl-8,9-dihydro-7H-benzocyclohepten-5-yl)-phenyl]-acryloyl}-methanesulfonamide; and

bs) N-{3-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-acryloyl}(4-trifluoromethyl-phenyl)-methanesulfonamide.

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier in combination with a therapeutically effective amount of a compound of claim 1 .

9. A method of treating breast, uterine, ovarian, prostate or colon cancer, osteoporosis, endometriosis, uterine fibroid, Alzheimer's disease, macular degeneration, urinary incontinence or type II diabetes, comprising: administering to a host in need of such treatment a therapeutically effective amount of a compound of claim 1 .